Rimegepant (Vydura)

Status:: Red
Decision Date:: August 2023

Comments

RED:

NICE TA906 - Rimegepant for preventing migraine. ICB commissioned
NICE TA919 - Rimegepant for treating migraine. ICB commissioned (decision date November 2023)

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)